25 results on '"Wang, Hexiao"'
Search Results
2. Computational Ghost Imaging System Based on Cloud Services
- Author
-
Wu, Jianan, primary, Zhu, Saikui, additional, Ma, Zhixin, additional, Wang, Hexiao, additional, and Wang, Mingcong, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Chronic Interferon Stimulated Gene Transcription Promotes Oncogene Induced Breast Cancer
- Author
-
Wang, Hexiao, primary, Canasto-Chibuque, Claudia, additional, Kim, Jun Hyun, additional, Hohl, Marcel, additional, Leslie, Christina, additional, Reis-Filho, Jorge S, additional, and Petrini, John HJ, additional
- Published
- 2023
- Full Text
- View/download PDF
4. RTEL1 influences the abundance and localization of TERRA RNA
- Author
-
Ghisays, Fiorella, Garzia, Aitor, Wang, Hexiao, Canasto-Chibuque, Claudia, Hohl, Marcel, Savage, Sharon A., Tuschl, Thomas, and Petrini, John H. J.
- Published
- 2021
- Full Text
- View/download PDF
5. Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma
- Author
-
Atkinson, Aithne, Renziehausen, Alexander, Wang, Hexiao, Lo Nigro, Cristiana, Lattanzio, Laura, Merlano, Marco, Rao, Bhavya, Weir, Lynda, Evans, Alan, Matin, Rubeta, Harwood, Catherine, Szlosarek, Peter, Pickering, J Geoffrey, Fleming, Colin, Sim, Van Ren, Li, Su, Vasta, James T., Raines, Ronald T., Boniol, Mathieu, Thompson, Alastair, Proby, Charlotte, Crook, Tim, and Syed, Nelofer
- Published
- 2019
- Full Text
- View/download PDF
6. Epigenetic dysregulation of novel candidate genes in melanoma
- Author
-
Wang, Hexiao and Inman, Gareth
- Subjects
616.99 - Abstract
Cutaneous melanoma (CM) is an aggressive neoplastic disorder of melanocytes accounting for 4% of skin cancers, but over 75% of skin cancer-related deaths. The outlook for advanced melanoma is typically poor, particularly for patients with distant and/or visceral metastatic disease. Although new melanoma therapies including vemurafenib and ipilimumab confer significant clinical benefit, accumulating evidence suggests that they are less effective when tumour load is high and patient performance status poor, as is often the case in advanced disease. New strategies for the early detection of sub-clinical relapsed and/or metastatic disease are therefore urgently required. Development of such biomarkers, combining sensitivity and specificity, would allow the deployment of these treatments when tumour volume is low thereby maximising anti-melanoma efficacy. Cancer-associated gene promoter methylation is recognized as an important mechanism in tumour initiation and progression. Exploring the epigenetic profiles of melanoma will lead to the generation of new strategies for molecular subtyping, discovery of diagnostic and prognostic biomarkers and development of novel therapeutic targets. In the present study, I have identified a panel of promising epigenetic melanoma biomarkers by exploiting both a systematic approach and candidate gene approach. Biomarkers TFPI2 and P4HA3 showed a high frequency and high level of methylation in melanoma cell lines. Significantly increased methylation in melanoma suggests a role for TFPI2 and P4HA3 as epigenetic biomarkers that can potentially predict poor prognosis of melanoma. Furthermore, in my work a highly significant correlation has been established between detection of methylated genomic DNA of TFPI2 and P4HA3 in melanoma patients’ sera and metastatic disease. This implies potential clinical utility for TFPI2 and P4HA3 as serum biomarkers for the detection of metastatic melanoma. In contrast, the presence of NT5E and DUSP2 methylation is likely to be a good prognostic biomarker for both primary melanoma and metastatic disease. NT5E methylation was associated with early stage melanoma but became undetectable when melanoma metastasis progressed to visceral sites. Similarly, the significantly higher methylation level of DUSP2 in primary melanomas than in metastatic disease implies that DUSP2 methylation may also be a biomarker of good prognosis in melanoma.In summary, my study proposes that epigenetic dysregulation by CpG island methylation of tumour-related genes TFPI2, P4HA3, NT5E and DUSP2 is important in melanoma development and progression and that detection of methylated DNA from these genes may provide novel biomarkers for predicting tumour progression and patient outcome. Molecular functions of these biomarkers in melanoma should be investigated in future work for the purpose of better understanding the biology of this highly aggressive tumour. Such studies may also lead to new therapeutic strategies for advanced melanoma. For example, antibodies to NT5E show efficacy in animal models of metastatic breast cancer and merit assessment in melanoma. Moreover, detection of circulating methylated genomic DNA from TFPI2 and P4HA3 in patient sera may be useful for predicting prognosis and for the early diagnosis of metastatic disease. Given the emerging evidence that new melanoma therapeutics, particularly ipilimumab, are most effective when used in low volume metastatic disease, such epigenetic biomarkers are likely to be of value in informing the clinical deployment of such agents.
- Published
- 2013
7. The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention
- Author
-
Renziehausen, Alexander, Wang, Hexiao, Rao, Bhavya, Weir, Lynda, Nigro, Cristiana Lo, Lattanzio, Laura, Merlano, Marco, Vega-Rioja, Antonio, del Carmen Fernandez-Carranco, Maria, Hajji, Nabil, Matin, Rubeta, Harwood, Catherine, Li, Su, Sim, Van Ren, O’Neill, Kevin, Evans, Alan, Thompson, Alastair, Szlosarek, Peter, Fleming, Colin, Stebbing, Justin, Proby, Charlotte, Tzakos, Andreas G., Syed, Nelofer, and Crook, Tim
- Published
- 2019
- Full Text
- View/download PDF
8. Heat Increases the Editing Efficiency of Human Papillomavirus E2 Gene by Inducing Upregulation of APOBEC3A and 3G
- Author
-
Yang, Yang, Wang, Hexiao, Zhang, Xinrui, Huo, Wei, Qi, Ruiqun, Gao, Yali, Zhang, Gaofeng, Song, Bing, Chen, Hongduo, and Gao, Xinghua
- Published
- 2017
- Full Text
- View/download PDF
9. Modification of the Early Gene Enhancer-promoter Improves the Oncolytic Potency of Adenovirus 11
- Author
-
Wong, Han Hsi, primary, Jiang, Guozhong, additional, Gangeswaran, Rathi, additional, Wang, Pengju, additional, Wang, Jiwei, additional, Yuan, Ming, additional, Wang, Hexiao, additional, Bhakta, Vipul, additional, Müller, Heike, additional, Lemoine, Nicholas R., additional, and Wang, Yaohe, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Quantitative investment decision model based on ARIMA and iterative neural network
- Author
-
Han, Naihan, primary, Zhang, Shuo, additional, Wang, Hexiao, additional, Chen, Zhihao, additional, Hou, Xiaolong, additional, and Sun, Zhijie, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Activation of aryl hydrocarbon receptor ameliorates rosacea-like eruptions in mice and suppresses the TLR signaling pathway in LL-37-induced HaCaT cells
- Author
-
Sun, Yan, primary, Chen, LiangHong, additional, Wang, HeXiao, additional, Zhu, PeiYao, additional, Jiang, ShiBin, additional, Qi, RuiQun, additional, Wu, Yan, additional, and Gao, XingHua, additional
- Published
- 2022
- Full Text
- View/download PDF
12. IgE and IgG Anti-Thyroid Autoantibodies in Chinese Patients With Chronic Spontaneous Urticaria and a Literature Review
- Author
-
Zhang, Liming, primary, Qiu, Li, additional, Wu, Jian, additional, Qi, Yumeng, additional, Wang, Hexiao, additional, Qi, Ruiqun, additional, Yao, Xu, additional, Zhu, Hong, additional, Li, Yuzhen, additional, Hao, Siyu, additional, Lu, Qianjin, additional, Long, Hai, additional, Lian, Shi, additional, Zhang, Haiping, additional, Zhu, Wei, additional, Lai, Wei, additional, Su, Xiangyang, additional, Lu, Rongbiao, additional, Guo, Zaipei, additional, Li, Jingyi, additional, Li, Mengmeng, additional, Liu, Quanzhong, additional, Wang, Huiping, additional, He, Li, additional, Nong, Xiang, additional, Li, Fuqiu, additional, Li, Yang, additional, Yao, Chunli, additional, Xu, Jinhua, additional, Tang, Hui, additional, Wang, Duoqin, additional, Li, Zhenlu, additional, Yu, Huiqian, additional, Xiao, Shengxiang, additional, An, Jingang, additional, Pu, Xiongming, additional, Yu, Shirong, additional, Zhang, Jianzhong, additional, Chen, Xue, additional, Gao, Xinghua, additional, Chen, Hongduo, additional, and Xiao, Ting, additional
- Published
- 2022
- Full Text
- View/download PDF
13. RTEL1 Influences the Abundance and Localization of TERRA RNA
- Author
-
Ghisays, Fiorella, primary, Garzia, Aitor, additional, Wang, Hexiao, additional, Canasto-Chibuque, Claudia, additional, Hohl, Marcel, additional, Savage, Sharon A., additional, Tuschl, Thomas, additional, and Petrini, John H. J., additional
- Published
- 2020
- Full Text
- View/download PDF
14. Paeoniflorin Resists H2O2-Induced Oxidative Stress in Melanocytes by JNK/Nrf2/HO-1 Pathway
- Author
-
Yuan, Jinping, primary, Lu, Yansong, additional, Wang, Hexiao, additional, Feng, Yuxin, additional, Jiang, Shibin, additional, Gao, Xing-Hua, additional, Qi, RuiQun, additional, Wu, Yan, additional, and Chen, Hong-Duo, additional
- Published
- 2020
- Full Text
- View/download PDF
15. The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention
- Author
-
Renziehausen, Alexander, primary, Wang, Hexiao, additional, Rao, Bhavya, additional, Weir, Lynda, additional, Nigro, Cristiana Lo, additional, Lattanzio, Laura, additional, Merlano, Marco, additional, Vega-Rioja, Antonio, additional, del Carmen Fernandez-Carranco, Maria, additional, Hajji, Nabil, additional, Matin, Rubeta, additional, Harwood, Catherine, additional, Li, Su, additional, Sim, Van Ren, additional, O’Neill, Kevin, additional, Evans, Alan, additional, Thompson, Alastair, additional, Szlosarek, Peter, additional, Fleming, Colin, additional, Stebbing, Justin, additional, Proby, Charlotte, additional, Tzakos, Andreas G., additional, Syed, Nelofer, additional, and Crook, Tim, additional
- Published
- 2018
- Full Text
- View/download PDF
16. Paeoniflorin Resists H2O2-Induced Oxidative Stress in Melanocytes by JNK/Nrf2/HO-1 Pathway.
- Author
-
Yuan, Jinping, Lu, Yansong, Wang, Hexiao, Feng, Yuxin, Jiang, Shibin, Gao, Xing-Hua, Qi, RuiQun, Wu, Yan, and Chen, Hong-Duo
- Subjects
OXIDATIVE stress ,MELANOCYTES ,SUPEROXIDE dismutase ,HYDROGEN peroxide ,REACTIVE oxygen species - Abstract
Paeoniflorin (PF) possesses multiple biological functions including anti-oxidization. PF is the major bioactive ingredient of total glycosides of paeony (TGP), which could promote re-pigmentation of vitiligo. The study was sought to investigate the effects and potential signaling pathways of PF on hydrogen peroxide (H
2 O2 )-induced oxidative stress in melanocytes. The results showed that pretreatment with 50 µM PF significantly inhibited cell apoptosis, enhanced cell viability, and suppressed reactive oxygen species (ROS) accumulation by enhancing the productions of superoxide dismutase (SOD) and antioxidant enzymes catalase (CAT). Furthermore, PF activated c-Jun amino terminal kinase (JNK) and the nuclear factor E2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway to counteract H2 O2 -induced oxidative damage in PIG1 and PIG3V. Taken together, our study firstly demonstrates that PF resists H2 O2 -induced oxidative stress in melanocytes probably by activating JNK/Nrf2/HO-1 signaling, suggesting a potential therapeutic application of PF on vitiligo. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
17. Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
- Author
-
Carbone, David, primary, Sharpnack, Michael, additional, He, Kai, additional, Butterfield, Lisa H., additional, Eggermont, Alexander M. M., additional, Gonzalez-Cao, Maria, additional, Karachaliou, Niki, additional, Crespo, Guillermo, additional, Aldeguer, Erika, additional, Drozdowskyj, Ana, additional, Giménez-Capitán, Ana, additional, Teixidó, Cristina, additional, Molina-Vila, Miguel Angel, additional, Ramírez, Santiago Viteri, additional, Algarra, Salvador Martin, additional, Pérez-Ruiz, Elisabeth, additional, Márquez-Rodas, Iván, additional, Rodriguez-Abreu, Delvys, additional, Blanco, Remei, additional, Puértolas, Teresa, additional, Royo, Maria Angeles, additional, Rosell, Rafael, additional, Ascierto, Maria Libera, additional, Hamm, Svetlana, additional, Wulff, Tanja, additional, Kronthaler, Kerstin, additional, Schrepfer, Sabine, additional, Parnitzke, Ulrike, additional, Bretz, Anne Catherine, additional, Baumgartner, Roland, additional, Ferrucci, Veronica, additional, Pennino, Francesco Paolo, additional, Dassi, Luisa, additional, Asadzadeh, Fatemeh, additional, Siciliano, Roberto, additional, Carotenuto, Marianeve, additional, Spano, Daniela, additional, Chiarolla, Cristina Maria, additional, Greco, Adelaide, additional, Cantile, Monica, additional, Di Bonito, Maurizio, additional, Botti, Gerardo, additional, Jonathan, Vandenbussche, additional, Kris, Gevaert, additional, Zollo, Massimo, additional, Amaral, Teresa, additional, Tampouri, Ioanna, additional, Keim, Ulrike, additional, Eigentler, Thomas, additional, Garbe, Claus, additional, Forschner, Andrea, additional, Cesano, Alessandra, additional, Warren, Sarah, additional, Moogk, Duane, additional, Li, Kaitao, additional, Yuan, Zhou, additional, Zhong, Shi, additional, Yu, Zhiya, additional, Liadi, Ivan, additional, Rittase, William, additional, Fang, Victoria, additional, Dougherty, Janna, additional, Perez-Garcia, Arianne, additional, Osman, Iman, additional, Varadarajan, Navin, additional, Restifo, Nicholas P., additional, Frey, Alan, additional, Zhu, Cheng, additional, Krogsgaard, Michelle, additional, Vanpouille-Box, Claire, additional, Formenti, Silvia C., additional, Demaria, Sandra, additional, Nigro, Cristiana Lo, additional, Renziehausen, Alexander, additional, Tzakos, Andreas G., additional, Wang, Hexiao, additional, Rao, Bhavya, additional, Matin, Rubeta, additional, Harwood, Catherine, additional, Vivenza, Daniela, additional, Tonissi, Federica, additional, Occelli, Marcella, additional, Weir, Lynda, additional, Li, Su, additional, Sim, Van Ren, additional, O’Neill, Kevin, additional, Evans, Alan, additional, Thompson, Alastair, additional, Szlosarek, Peter, additional, Fleming, Colin, additional, Proby, Charlotte, additional, Syed, Nelofer, additional, Merlano, Marco, additional, Crook, Tim, additional, Ferguson, Robert, additional, Simpson, Danny, additional, Martinez, Carlos, additional, Vogelsang, Matjaz, additional, Kazlow, Esther, additional, Wilson, Melissa, additional, Pavlick, Anna, additional, Weber, Jeffrey, additional, Sullivan, Ryan, additional, Flaherty, Keith, additional, Ribas, Antoni, additional, Kirchhoff, Tomas, additional, D’Avino, Antonio, additional, Guida, Licia, additional, Cosacco, Augusto, additional, D’Aniello, Roberta, additional, Maiolino, Piera, additional, Tramontano, Teresa, additional, Sarno, Maria R., additional, Palazzo, Ida, additional, Di Napoli, Angela, additional, Acunzo, Gianclaudio, additional, De Fina, Mariarosanna, additional, Silvestri, Antonia, additional, Specchia, Monica, additional, Musacchio, Michela, additional, Giglio, Gianfranco, additional, Carrozza, Francesco, additional, Di Lullo, Liberato, additional, De Maddi, Gian Marco, additional, Venturelli, Adele, additional, Gambale, Elisabetta, additional, Gatta, Alessia, additional, Brocco, Davide, additional, Carella, Consiglia, additional, De Tursi, Michele, additional, Gajewski, Thomas F., additional, Cristiani, Costanza M., additional, Tallerico, Rossana, additional, Ventura, Valeria, additional, Capone, Mariaelena, additional, Madonna, Gabriele, additional, Mallardo, Domenico, additional, Selinger, Eliska, additional, Garofalo, Cinzia, additional, Staaf, Elina, additional, Simeone, Ester, additional, Grimaldi, Antonio M., additional, del Zotto, Genny, additional, Gulletta, Elio, additional, Ciliberto, Gennaro, additional, Moretta, Alessandro, additional, Ascierto, Paolo A., additional, Carbone, Ennio, additional, Costantini, Susan, additional, Sorice, Angela, additional, Capone, Francesca, additional, Budillon, Alfredo, additional, Cauchi, Carolina, additional, Sciancalepore, Grazia, additional, Rovera, Michela, additional, Varamo, Chiara, additional, Seia, Zelda, additional, Palazzini, Stefania, additional, Errico, Fabiana, additional, Basso, Davide, additional, Quaranta, Laura, additional, Forte, Giuseppe, additional, Lavagna, Fulvio, additional, Violante, Silvia, additional, Bosio, Paolo, additional, Lattanzio, Laura, additional, Merlano, Marco C, additional, Gowen, Mike, additional, Tchack, Jeremy, additional, Zhou, Hua, additional, Giles, Keith, additional, Paschke, Scott, additional, Moran, Una, additional, Fenyo, David, additional, Tsirigos, Aris, additional, Pacold, Michael, additional, Morello, Silvana, additional, Sorrentino, Claudia, additional, Giannarelli, Diana, additional, Pinto, Aldo, additional, Fratangelo, Federica, additional, Falcone, Rosaria, additional, Vanella, Vito, additional, Schadendorf, Dirk, additional, Lewis, Karl, additional, Maio, Michele, additional, Demidov, Lev, additional, Mandalà, Mario, additional, Bondarenko, Igor, additional, Herbert, Christopher, additional, Mackiewicz, Andrzej, additional, Rutkowski, Piotr, additional, Guminski, Alexander, additional, Goodman, Grant, additional, Simmons, Brian, additional, Ye, Chenglin, additional, Hooper, Gregory, additional, Wongchenko, Matthew J., additional, Yan, Yibing, additional, Hermann, Frank, additional, Ammendola, Astrid, additional, Bartz, René, additional, Alessandra, Bulotta, additional, Letizia, Colombo, additional, Aurora, Mirabile, additional, Chiara, Lazzari, additional, Raffaele, Mercuri Santo, additional, Danilo, Parolini, additional, Nathalie, Rizzo, additional, Stefano, Martella, additional, Giulio, Modorati, additional, Pina, Brianti, additional, Enza, Cestone, additional, Federica, Bellinzona, additional, Elisabetta, Miserocchi, additional, Luca, Gianni, additional, Vanesa, Gregorc, additional, Agarwala, Sanjiv, additional, Mark Smithers, B., additional, Haushild, Axel, additional, Watcher, Eric, additional, Fattore, Luigi, additional, Ruggiero, Ciro Francesco, additional, Liguoro, Domenico, additional, Cerri, Andrea, additional, Pisanu, Maria Elena, additional, and Mancini, Rita, additional
- Published
- 2018
- Full Text
- View/download PDF
18. Melanoma and immunotherapy bridge 2015
- Author
-
Nanda, Vashisht G. Y., Peng, Weiyi, Hwu, Patrick, Davies, Michael A., Ciliberto, Gennaro, Fattore, Luigi, Malpicci, Debora, Aurisicchio, Luigi, Ascierto, Paolo Antonio, Croce, Carlo M., Mancini, Rita, Spranger, Stefani, Gajewski, Thomas F., Wang, Yangyang, Ferrone, Soldano, Vanpouille-Box, Claire, Wennerberg, Erik, Pilones, Karsten A., Formenti, Silvia C., Demaria, Sandra, Tang, Haidong, Wang, Yang, Fu, Yang-Xin, Dummer, Reinhard, Puzanov, Igor, Tarhini, Ahmad, Chauvin, Joe-Marc, Pagliano, Ornella, Fourcade, Julien, Sun, Zhaojun, Wang, Hong, Sanders, Cindy, Kirkwood, John M., Chen, Tseng-hui Timothy, Maurer, Mark, Korman, Alan J., Zarour, Hassane M., Stroncek, David F., Huber, Veronica, Rivoltini, Licia, Thurin, Magdalena, Rau, Tilman, Lugli, Alessandro, Pagès, Franck, Camarero, Jorge, Sancho, Arantxa, Jommi, Claudio, de Coaña, Yago Pico, Wolodarski, Maria, Yoshimoto, Yuya, Gentilcore, Giusy, Poschke, Isabel, Masucci, Giuseppe V., Hansson, Johan, Kiessling, Rolf, Scognamiglio, Giosuè, Sabbatino, Francesco, Marino, Federica Zito, Anniciello, Anna Maria, Cantile, Monica, Cerrone, Margherita, Scala, Stefania, D’alterio, Crescenzo, Ianaro, Angela, Cirin, Giuseppe, Liguori, Giuseppina, Bott, Gerardo, Chapman, Paul B., Robert, Caroline, Larkin, James, Haanen, John B., Ribas, Antoni, Hogg, David, Hamid, Omid, Testori, Alessandro, Lorigan, Paul, Sosman, Jeffrey A., Flaherty, Keith T., Yue, Huibin, Coleman, Shelley, Caro, Ivor, Hauschild, Axel, McArthur, Grant A., Sznol, Mario, Callahan, Margaret K., Kluger, Harriet, Postow, Michael A., Gordan, RuthAnn, Segal, Neil H., Rizvi, Naiyer A., Lesokhin, Alexander, Atkins, Michael B., Burke, Matthew M., Ralabate, Amanda, Rivera, Angel, Kronenberg, Stephanie A., Agunwamba, Blessing, Ruisi, Mary, Horak, Christine, Jiang, Joel, Wolchok, Jedd, Ascierto, Paolo A., Liszkay, Gabriella, Maio, Michele, Mandalà, Mario, Demidov, Lev, Stoyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Wongchenko, Matthew, Chang, Ilsung, Koralek, Daniel O., Rooney, Isabelle, Yan, Yibing, Dréno, Brigitte, Sullivan, Ryan, Patel, Manish, Hodi, Stephen, Amaria, Rodabe, Boasberg, Peter, Wallin, Jeffrey, He, Xian, Cha, Edward, Richie, Nicole, Ballinger, Marcus, Smith, David C., Bauer, Todd M., Wasser, Jeffrey S., Luke, Jason J., Balmanoukian, Ani S., Kaufman, David R., Zhao, Yufan, Maleski, Janet, Leopold, Lance, Gangadhar, Tara C., Long, Georgina V., Michielin, Olivier, VanderWalde, Ari, Andtbacka, Robert H. I., Cebon, Jonathan, Fernandez, Eugenio, Malvehy, Josep, Olszanski, Anthony J., Gause, Christine, Chen, Lisa, Chou, Jeffrey, Stephen Hodi, F., Brady, Benjamin, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Lebbé, Celeste, Ny, Lars, Chacon, Matias, Queirolo, Paola, Loquai, Carmen, Cheema, Parneet, Berrocal, Alfonso, Eizmendi, Karmele Mujika, Bar-Sela, Gil, Hardy, Helene, Weber, Jeffrey S., Grob, Jean-Jacques, Marquez-Rodas, Ivan, Schmidt, Henrik, Briscoe, Karen, Baurain, Jean-François, Wolchok, Jedd D., Pinto, Rosamaria, De Summa, Simona, Garrisi, Vito Michele, Strippoli, Sabino, Azzariti, Amalia, Guida, Gabriella, Guida, Michele, Tommasi, Stefania, Jacquelot, Nicolas, Enot, David, Flament, Caroline, Pitt, Jonathan M., Vimond, Nadège, Blattner, Carolin, Yamazaki, Takahiro, Roberti, Maria-Paula, Vetizou, Marie, Daillere, Romain, Poirier-Colame, Vichnou, la Semeraro, Michaë, Caignard, Anne, Slingluff, Craig L, Sallusto, Federica, Rusakiewicz, Sylvie, Weide, Benjamin, Marabelle, Aurélien, Kohrt, Holbrook, Dalle, Stéphane, Cavalcanti, Andréa, Kroemer, Guido, Di Giacomo, Anna Maria, Maio, Michaele, Wong, Phillip, Yuan, Jianda, Umansky, Viktor, Eggermont, Alexander, Zitvogel, Laurence, Anna, Passarelli, Marco, Tucci, Stefania, Stucci, Francesco, Mannavola, Mariaelena, Capone, Gabriele, Madonna, Antonio, Ascierto Paolo, Franco, Silvestris, Roberti, María Paula, Enot, David P., Semeraro, Michaela, Jégou, Sarah, Flores, Camila, Kwon, Byoung S., Anderson, Ana Carrizossa, Borg, Christophe, Aubin, François, Ayyoub, Maha, De Presbiteris, Anna Lisa, Cordaro, Fabiola Gilda, Camerlingo, Rosa, Fratangelo, Federica, Mozzillo, Nicola, Pirozzi, Giuseppe, Patriarca, Eduardo J., Caputo, Emilia, Motti, Maria Letizia, Falcon, Rosaria, Miceli, Roberta, Capone, Mariaelena, Madonna, Gabriele, Mallardo, Domenico, Carrier, Maria Vincenza, Panza, Elisabetta, De Cicco, Paola, Armogida, Chiara, Ercolano, Giuseppe, Botti, Gerardo, Cirino, Giuseppe, Sandru, Angela, Blank, Miri, Balatoni, Timea, Olasz, Judit, Farkas, Emil, Szollar, Andras, Savolt, Akos, Godeny, Maria, Csuka, Orsolya, Horvath, Szabolcs, Eles, Klara, Shoenfeld, Yehuda, Kasler, Miklos, Costantini, Susan, Capone, Francesca, Moradi, Farnaz, Berglund, Pontus, Leandersson, Karin, Linnskog, Rickard, Andersson, Tommy, Prasad, Chandra Prakash, Nigro, Cristiana Lo, Lattanzio, Laura, Wang, Hexiao, Proby, Charlotte, Syed, Nelofer, Occelli, Marcella, Cauchi, Carolina, Merlano, Marco, Harwood, Catherine, Thompson, Alastair, Crook, Tim, Bifulco, Katia, Ingangi, Vincenzo, Minopoli, Michele, Ragone, Concetta, Pessi, Antonello, Mannavola, Francesco, D’Oronzo, Stella, Felici, Claudia, Tucci, Marco, Doronzo, Antonio, Silvestris, Franco, Ferretta, Anna, Guida, Stefania, Maida, Imma, Cocco, Tiziana, Passarelli, Anna, Quaresmini, Davide, Franzese, Ornella, Palermo, Belinda, Di Donna, Cosmo, Sperduti, Isabella, Foddai, MariaLaura, Stabile, Helena, Gismondi, Angela, Santoni, Angela, Nisticò, Paola, Sponghini, Andrea P., Platini, Francesca, Marra, Elena, Rondonotti, David, Alabiso, Oscar, Fierro, Maria T., Savoia, Paola, Stratica, Florian, Quaglino, Pietro, Di Monta, Gianluca, Corrado, Caracò, Di Marzo, Massimiliano, Ugo, Marone, Di Cecilia, Maria Luisa, Nicola, Mozzillo, Fusciello, Celeste, Marra, Antonio, Guarrasi, Rosario, Baldi, Carlo, Russo, Rosa, Di Giulio, Giovanni, Faiola, Vincenzo, Zeppa, Pio, Pepe, Stefano, Gambale, Elisabetta, Carella, Consiglia, Di Paolo, Alessandra, De Tursi, Michele, Marra, Laura, De Murtas, Fara, Sorrentino, Valeria, Voinea, Silviu, Panaitescu, Eugenia, Bolovan, Madalina, Stanciu, Adina, Cinca, Sabin, Botti, Chiara, Aquino, Gabriella, Anniciello, Annamaria, Fortes, Cristina, Mastroeni, Simona, Caggiati, Alessio, Passarelli, Francesca, Zappalà, Alba, Capuano, Maria, Bono, Riccardo, Nudo, Maurizio, Marino, Claudia, Michelozzi, Paola, De Biasio, Valeria, Battarra, Vincenzo C., Formenti, Silvia, Ascierto, Maria Libera, McMiller, Tracee L., Berger, Alan E., Danilova, Ludmila, Anders, Robert A., Netto, George J., Xu, Haiying, Pritchard, Theresa S., Fan, Jinshui, Cheadle, Chris, Cope, Leslie, Drake, Charles G., Pardoll, Drew M., Taube, Janis M., Topalian, Suzanne L., Gnjatic, Sacha, Nataraj, Sarah, Imai, Naoko, Rahman, Adeeb, Jungbluth, Achim A., Pan, Linda, Venhaus, Ralph, Park, Andrew, Lehmann, Frédéric F., Lendvai, Nikoletta, Cohen, Adam D., Cho, Hearn J., Daniel, Speiser, and Hirsh, Vera
- Subjects
Medicine(all) ,Biochemistry, Genetics and Molecular Biology(all) ,Meeting Abstracts - Abstract
Table of contents MELANOMA BRIDGE 2015 KEYNOTE SPEAKER PRESENTATIONS Molecular and immuno-advances K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies K2 Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance Gennaro Ciliberto, Luigi Fattore, Debora Malpicci, Luigi Aurisicchio, Paolo Antonio Ascierto, Carlo M. Croce, Rita Mancini K3 Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance Stefani Spranger, Thomas F. Gajewski K4 Intracellular tumor antigens as a source of targets of antibody-based immunotherapy of melanoma Yangyang Wang, Soldano Ferrone Combination therapies K5 Harnessing radiotherapy to improve responses to immunotherapy in cancer Claire Vanpouille-Box, Erik Wennerberg, Karsten A. Pilones, Silvia C. Formenti, Sandra Demaria K6 Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockade Haidong Tang, Yang Wang, Yang-Xin Fu K7 Biomarkers for treatment decisions? Reinhard Dummer K8 Combining oncolytic therapies in the era of checkpoint inhibitors Igor Puzanov K9 Immune checkpoint blockade for melanoma: should we combine or sequence ipilimumab and PD-1 antibody therapy? Michael A. Postow News in immunotherapy K10 An update on adjuvant and neoadjuvant therapy for melanom Ahmad Tarhini K11 Targeting multiple inhibitory receptors in melanoma Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sanders, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour K12 Improving adoptive immune therapy using genetically engineered T cells David F. Stroncek Tumor microenvironment and biomarkers K13 Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression? Veronica Huber, Licia Rivoltini K14 Update on the SITC biomarker taskforce: progress and challenges Magdalena Thurin World-wide immunoscore task force: an update K15 The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathology Tilman Rau, Alessandro Lugli K16 The immunoscore: toward an integrated immunomonitoring from the diagnosis to the follow up of cancer’s patients Franck Pagès Economic sustainability of melanoma treatments: regulatory, health technology assessment and market access issues K17 Nivolumab, the regulatory experience in immunotherapy Jorge Camarero, Arantxa Sancho K18 Evidence to optimize access for immunotherapies Claudio Jommi ORAL PRESENTATIONS Molecular and immuno-advances O1 Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel Poschke, Giuseppe V. Masucci, Johan Hansson, Rolf Kiessling O2 Evaluation of prognostic and therapeutic potential of COX-2 and PD-L1 in primary and metastatic melanoma Giosuè Scognamiglio, Francesco Sabbatino, Federica Zito Marino, Anna Maria Anniciello, Monica Cantile, Margherita Cerrone, Stefania Scala, Crescenzo D’alterio, Angela Ianaro, Giuseppe Cirino, Paolo Antonio Ascierto, Giuseppina Liguori, Gerardo Botti O3 Vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma: final overall survival results of the BRIM-3 study Paul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo Antonio Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, Jeffrey A. Sosman, Keith T. Flaherty, Huibin Yue, Shelley Coleman, Ivor Caro, Axel Hauschild, Grant A. McArthur O4 Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma Mario Sznol, Margaret K. Callahan, Harriet Kluger, Michael A. Postow, RuthAnn Gordan, Neil H. Segal, Naiyer A. Rizvi, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, Angel Rivera, Stephanie A. Kronenberg, Blessing Agunwamba, Mary Ruisi, Christine Horak, Joel Jiang, Jedd Wolchok Combination therapies O5 Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) + vemurafenib (VEM) vs placebo (PBO) + VEM in advanced BRAF-mutated melanoma patients (pts) Paolo A. Ascierto, Grant A. McArthur, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. Koralek, Isabelle Rooney, Yibing Yan, Antoni Ribas, Brigitte Dréno O6 Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanoma Ryan Sullivan, Omid Hamid, Manish Patel, Stephen Hodi, Rodabe Amaria, Peter Boasberg, Jeffrey Wallin, Xian He, Edward Cha, Nicole Richie, Marcus Ballinger, Patrick Hwu O7 Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma Thomas F. Gajewski, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Tara C. Gangadhar O8 Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma Reinhard Dummer, Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert H.I. Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J. Olszanski, Thomas F. Gajewski, John M. Kirkwood, Christine Gause, Lisa Chen, David R. Kaufman, Jeffrey Chou, F. Stephen Hodi News in immunotherapy O9 Two-year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066 Victoria Atkinson, Paolo A. Ascierto, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Celeste Lebbé, Lars Ny, Matias Chacon, Paola Queirolo, Carmen Loquai, Parneet Cheema, Alfonso Berrocal, Karmele Mujika Eizmendi, Luis De La Cruz-Merino, Gil Bar-Sela, Christine Horak, Joel Jiang, Helene Hardy, Caroline Robert O10 Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067 Georgina V. Long, Jeffrey S. Weber, James Larkin, Victoria Atkinson, Jean-Jacques Grob, Reinhard Dummer, Caroline Robert, Ivan Marquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François Baurain, F. Stephen Hodi, Jedd D. Wolchok Tumor microenvironment and biomarkers O11 New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma Rosamaria Pinto, Simona De Summa, Vito Michele Garrisi, Sabino Strippoli, Amalia Azzariti, Gabriella Guida, Michele Guida, Stefania Tommasi O12 Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma and response to ipilimumab Nicolas Jacquelot, David Enot, Caroline Flament, Jonathan M. Pitt, Nadège Vimond, Carolin Blattner, Takahiro Yamazaki, Maria-Paula Roberti, Marie Vetizou, Romain Daillere, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff Jr, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michaele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont, Laurence Zitvogel O13 Serum levels of PD1- and CD28-positive exosomes before Ipilimumab correlate with therapeutic response in metastatic melanoma patients Passarelli Anna, Tucci Marco, Stucci Stefania, Mannavola Francesco, Capone Mariaelena, Madonna Gabriele, Ascierto Paolo Antonio, Silvestris Franco O14 Immunological prognostic factors in stage III melanomas María Paula Roberti, Nicolas Jacquelot, David P Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Ana Carrizossa Anderson, Caroline Robert, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, Michele Maio, Jedd D. Wolchok, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel POSTER PRESENTATIONS Molecular and immuno-advances P1 Human melanoma cells resistant to B-RAF and MEK inhibition exhibit mesenchymal-like features Anna Lisa De Presbiteris, Fabiola Gilda Cordaro, Rosa Camerlingo, Federica Fratangelo, Nicola Mozzillo, Giuseppe Pirozzi, Eduardo J. Patriarca, Paolo A. Ascierto, Emilia Caputo P2 Anti-proliferative and pro-apoptotic effect of ABT888 on melanoma cell lines and its potential role in the treatment of melanoma resistant to B-RAF inhibitors Federica Fratangelo, Rosa Camerlingo, Emilia Caputo, Maria Letizia Motti, Rosaria Falcone, Roberta Miceli, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Maria Vincenza Carriero, Giuseppe Pirozzi and Paolo Antonio Ascierto P3 Involvement of the L-cysteine/CSE/H2S pathway in human melanoma progression Elisabetta Panza, Paola De Cicco, Chiara Armogida, Giuseppe Ercolano, Rosa Camerlingo, Giuseppe Pirozzi, Giosuè Scognamiglio, Gerardo Botti, Giuseppe Cirino, Angela Ianaro P4 Cancer stem cell antigen revealing pattern of antibody variable region genes were defined by immunoglobulin repertoire analysis in patients with malignant melanoma Beatrix Kotlan, Gabriella Liszkay, Miri Blank, Timea Balatoni, Judit Olasz, Emil Farkas, Andras Szollar, Akos Savolt, Maria Godeny, Orsolya Csuka, Szabolcs Horvath, Klara Eles, Yehuda Shoenfeld and Miklos Kasler P5 Upregulation of Neuregulin-1 expression is a hallmark of adaptive response to BRAF/MEK inhibitors in melanoma Debora Malpicci, Luigi Fattore, Susan Costantini, Francesca Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto P6 HuR positively regulates migration of HTB63 melanoma cells Farnaz Moradi, Pontus Berglund, Karin Leandersson, Rickard Linnskog, Tommy Andersson, Chandra Prakash Prasad P7 Prolyl 4- (C-P4H) hydroxylases have opposing effects in malignant melanoma: implication in prognosis and therapy Cristiana Lo Nigro, Laura Lattanzio, Hexiao Wang, Charlotte Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Merlano, Catherine Harwood, Alastair Thompson, Tim Crook P8 Urokinase receptor antagonists: novel agents for the treatment of melanoma Maria Letizia Motti, Katia Bifulco, Vincenzo Ingangi, Michele Minopoli, Concetta Ragone, Federica Fratangelo, Antonello Pessi, Gennaro Ciliberto, Paolo Antonio Ascierto, Maria Vincenza Carriero P9 Exosomes released by melanoma cell lines enhance chemotaxis of primary tumor cells Francesco Mannavola, Stella D’Oronzo, Claudia Felici, Marco Tucci, Antonio Doronzo, Franco Silvestris P10 New insights in mitochondrial metabolic reprogramming in melanoma Anna Ferretta, Gabriella Guida, Stefania Guida, Imma Maida, Tiziana Cocco, Sabino Strippoli, Stefania Tommasi, Amalia Azzariti, Michele Guida P11 Lenalidomide restrains the proliferation in melanoma cells through a negative regulation of their cell cycle Stella D’Oronzo, Anna Passarelli, Claudia Felici, Marco Tucci, Davide Quaresmini, Franco Silvestris Combination therapies P12 Chemoimmunotherapy elicits polyfunctional anti-tumor CD8 + T cells depending on the activation of an AKT pathway sustained by ICOS Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, MariaLaura Foddai, Helena Stabile, Angela Gismondi, Angela Santoni, Paola Nisticò P13 Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients Andrea P. Sponghini, Francesca Platini, Elena Marra, David Rondonotti, Oscar Alabiso, Maria T. Fierro, Paola Savoia, Florian Stratica, Pietro Quaglino P14 Electrothermal bipolar vessel sealing system dissection reduces seroma output or time to drain removal following axillary and ilio-inguinal node dissection in melanoma patients: a pilot study Di Monta Gianluca, Caracò Corrado, Di Marzo Massimiliano, Marone Ugo, Di Cecilia Maria Luisa, Mozzillo Nicola News in immunotherapy P15 Clinical and immunological response to ipilimumab in a metastatic melanoma patient with HIV infection Francesco Sabbatino, Celeste Fusciello1, Antonio Marra, Rosario Guarrasi, Carlo Baldi, Rosa Russo, Di Giulio Giovanni, Vincenzo Faiola, Pio Zeppa, Stefano Pepe P16 Immunotherapy and hypophysitis: a case report Elisabetta Gambale, Consiglia Carella, Alessandra Di Paolo, Michele De Tursi Tumor microenvironment and biomarkers P17 New immuno- histochemical markers for the differential diagnosis of atypical melanocytic lesions with uncertain malignant potential Laura Marra, Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, Fara De Murtas, Valeria Sorrentino, Anna Maria Anniciello, Gerardo Botti P18 Utility of simultaneous measurement of three serum tumor markers in melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P19 The significance of various cut-off levels of melanoma inhibitory activity in evaluation of cutaneous melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P20 The long noncoding RNA HOTAIR is associated to metastatic progression of melanoma and it can be identified in the blood of patients with advanced disease Chiara Botti, Giosuè Scognamiglio, Laura Marra, Gabriella Aquino, Rosaria Falcone, Annamaria Anniciello, Paolo Antonio Ascierto, Gerardo Botti, Monica Cantile Other P21 The effect of Sentinel Lymph Node Biopsy in melanoma mortality: timing of dissection Cristina Fortes, Simona Mastroeni, Alessio Caggiati, Francesca Passarelli, Alba Zappalà, Maria Capuano, Riccardo Bono, Maurizio Nudo, Claudia Marino, Paola Michelozzi P22 Epidemiological survey on related psychopathology in melanoma Valeria De Biasio, Vincenzo C. Battarra IMMUNOTHERAPY BRIDGE KEYNOTE SPEAKER PRESENTATIONS Immunotherapy beyond melanoma K19 Predictor of response to radiation and immunotherapy Silvia Formenti K20 Response and resistance to PD-1 pathway blockade: clues from the tumor microenvironment Maria Libera Ascierto, Tracee L. McMiller, Alan E. Berger, Ludmila Danilova, Robert A. Anders, George J. Netto, Haiying Xu, Theresa S. Pritchard, Jinshui Fan, Chris Cheadle, Leslie Cope, Charles G. Drake, Drew M. Pardoll, Janis M. Taube and Suzanne L. Topalian K21 Combination immunotherapy with autologous stem cell transplantation, protein immunization, and PBMC reinfusion in myeloma patients Sacha Gnjatic, Sarah Nataraj, Naoko Imai, Adeeb Rahman, Achim A. Jungbluth, Linda Pan, Ralph Venhaus, Andrew Park, Frédéric F. Lehmann, Nikoletta Lendvai, Adam D. Cohen, and Hearn J. Cho K22 Anti-cancer immunity despite T cell “exhaustion” Speiser Daniel Immunotherapy in oncology (I-O): data from clinical trial K23 The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) Vera Hirsh
- Published
- 2016
19. REG4 promotes peritoneal metastasis of gastric cancer through GPR37
- Author
-
Wang, Hexiao, primary, Hu, Lei, additional, Zang, Mingde, additional, Zhang, Baogui, additional, Duan, Yantao, additional, Fan, Zhiyuan, additional, Li, Jianfang, additional, Su, Liping, additional, Yan, Min, additional, Zhu, Zhenggang, additional, Liu, Bingya, additional, and Yang, Qiumeng, additional
- Published
- 2016
- Full Text
- View/download PDF
20. CEACAM6 promotes tumor angiogenesis and vasculogenic mimicry in gastric cancer via FAK signaling
- Author
-
Zang, Mingde, primary, Zhang, Yunqiang, additional, Zhang, Baogui, additional, Hu, Lei, additional, Li, Jianfang, additional, Fan, Zhiyuan, additional, Wang, Hexiao, additional, Su, Liping, additional, Zhu, Zhenggang, additional, Li, Chen, additional, Yan, Chao, additional, Gu, Qinlong, additional, Liu, Bingya, additional, and Yan, Min, additional
- Published
- 2015
- Full Text
- View/download PDF
21. Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma
- Author
-
Nigro, Cristiana Lo, primary, Wang, Hexiao, additional, McHugh, Angela, additional, Lattanzio, Laura, additional, Matin, Rubeta, additional, Harwood, Catherine, additional, Syed, Nelofer, additional, Hatzimichael, Eleftheria, additional, Briasoulis, Evangelos, additional, Merlano, Marco, additional, Evans, Alan, additional, Thompson, Alastair, additional, Leigh, Irene, additional, Fleming, Colin, additional, Inman, Gareth J., additional, Proby, Charlotte, additional, and Crook, Tim, additional
- Published
- 2013
- Full Text
- View/download PDF
22. Modification of the Early Gene Enhancer-promoter Improves the Oncolytic Potency of Adenovirus 11
- Author
-
Wong, Han Hsi, primary, Jiang, Guozhong, additional, Gangeswaran, Rathi, additional, Wang, Pengju, additional, Wang, Jiwei, additional, Yuan, Ming, additional, Wang, Hexiao, additional, Bhakta, Vipul, additional, Müller, Heike, additional, Lemoine, Nicholas R, additional, and Wang, Yaohe, additional
- Published
- 2012
- Full Text
- View/download PDF
23. Chronic Interferon Stimulated Gene Transcription Promotes Oncogene Induced Breast Cancer.
- Author
-
Wang H, Canasto-Chibuque C, Kim JH, Hohl M, Leslie C, Reis-Filho JS, and Petrini JH
- Abstract
The Mre11 complex (comprising Mre11, Rad50, Nbs1) is integral to the maintenance of genome stability. We previously showed that a hypomorphic Mre11 mutant mouse strain ( Mre11
ATLD1/ATLD1 ) was highly susceptible to oncogene induced breast cancer. Here we used a mammary organoid system to examine which Mre11 dependent responses are tumor suppressive. We found that Mre11ATLD1/ATLD1 organoids exhibited an elevated interferon stimulated gene (ISG) signature and sustained changes in chromatin accessibility. This Mre11ATLD1/ATLD1 phenotype depended on DNA binding of a nuclear innate immune sensor, IFI205. Ablation of Ifi205 in Mre11ATLD1/ATLD1 organoids restored baseline and oncogene-induced chromatin accessibility patterns to those observed in WT . Implantation of Mre11ATLD1/ATLD1 organoids and activation of oncogene led to aggressive metastatic breast cancer. This outcome was reversed in implanted Ifi205-/- Mre11ATLD1/ATLD1 organoids. These data reveal a connection between innate immune signaling and tumor suppression in mammary epithelium. Given the abundance of aberrant DNA structures that arise in the context of genome instability syndromes, the data further suggest that cancer predisposition in those contexts may be partially attributable to tonic innate immune transcriptional programs.- Published
- 2023
- Full Text
- View/download PDF
24. Paeoniflorin Resists H 2 O 2 -Induced Oxidative Stress in Melanocytes by JNK/Nrf2/HO-1 Pathway.
- Author
-
Yuan J, Lu Y, Wang H, Feng Y, Jiang S, Gao XH, Qi R, Wu Y, and Chen HD
- Abstract
Paeoniflorin (PF) possesses multiple biological functions including anti-oxidization. PF is the major bioactive ingredient of total glycosides of paeony (TGP), which could promote re-pigmentation of vitiligo. The study was sought to investigate the effects and potential signaling pathways of PF on hydrogen peroxide (H
2 O2 )-induced oxidative stress in melanocytes. The results showed that pretreatment with 50 µM PF significantly inhibited cell apoptosis, enhanced cell viability, and suppressed reactive oxygen species (ROS) accumulation by enhancing the productions of superoxide dismutase (SOD) and antioxidant enzymes catalase (CAT). Furthermore, PF activated c-Jun amino terminal kinase ( JNK ) and the nuclear factor E2-related factor 2 ( Nrf2 )/heme oxygenase-1 ( HO-1 ) pathway to counteract H2 O2 -induced oxidative damage in PIG1 and PIG3V. Taken together, our study firstly demonstrates that PF resists H2 O2 -induced oxidative stress in melanocytes probably by activating JNK/Nrf2/HO-1 signaling, suggesting a potential therapeutic application of PF on vitiligo., (Copyright © 2020 Yuan, Lu, Wang, Feng, Jiang, Gao, Qi, Wu and Chen.)- Published
- 2020
- Full Text
- View/download PDF
25. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma.
- Author
-
Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman GJ, Proby C, and Crook T
- Subjects
- Case-Control Studies, Cell Line, Tumor, CpG Islands genetics, DNA Methylation, Humans, Melanoma blood, Melanoma secondary, Nevus blood, Nevus diagnosis, Sensitivity and Specificity, Skin Neoplasms blood, Skin Neoplasms secondary, Biomarkers, Tumor blood, DNA, Neoplasm blood, Glycoproteins genetics, Melanoma diagnosis, Neoplasm Metastasis diagnosis, Skin Neoplasms diagnosis
- Abstract
Transcriptional silencing of tissue factor pathway inhibitor 2 (TFPI2) occurs in several human tumors including melanoma. We investigated methylated TFPI2 as a biomarker of metastatic melanoma using qRT-PCR to assess TFPI2 expression and pyrosequencing to analyze CpG island methylation in malignant melanoma cell lines, in benign nevi, in 112 primary and metastatic melanomas, and in serum from 6 healthy individuals and 35 patients: 20 patients with primary and 15 patients with metastatic melanoma. The TFPI2 CpG island is unmethylated in nevi but methylation is associated with metastatic melanoma. Circulating methylated TFPI2 DNA is undetectable in sera from healthy individuals and detectable in sera from patients with primary and metastatic melanomas, but the presence of methylated TFPI2 DNA in serum is strongly associated with metastatic disease (P<0.01). Detection of TFPI2-methylated DNA in the serum of patients with resected melanoma is a sensitive and specific biomarker of metastatic melanoma. Confirmation of our results in independent patient cohorts would encourage prospective evaluation as a biomarker of disease state.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.